Found 285 articles for: "biologics"
Mechanism of Action of Brodalumab May Correlate With Efficacy in Patients With Inflammatory Skin Diseases
October 2023 | Volume 22 | Issue 10 | Original Article | 994 | Copyright © October 2023
Biologic therapy is used for systemic treatment of multiple inflammatory conditions, including moderate-to-severe plaque psoriasis. Brodalumab is an interleukin-17 (IL-17) receptor A antagonist indica...
Read MoreINDIVIDUAL ARTICLE: Real-World Evidence on the Use of Calcipotriene and Betamethasone Dipropionate Aerosol Foam 0.005%/0.064% in the Treatment of Psoriasis: A Review of Investigator-Initiated Studies Around the Globe
September 2023 | Volume 22 | Issue 9 | Department | SF378719s5 | Copyright © September 2023
Topical medications are commonly used to manage mild-to-moderate psoriasis and serve as adjunct therapies used in combination with phototherapy and systemic treatments. Fixed-dose calcipotriene (Cal) ...
Read MoreClinical Trial of Alpha and Beta Defensin Skin Care Regimen for Improvement of Periocular Wrinkles
September 2023 | Volume 22 | Issue 9 | Original Article | 874 | Copyright © September 2023
Background: Defensins recruit leucine-rich repeat-containing G protein-coupled receptor 6 positive (Lgr6+) stem cells which ultimately regenerate new basal stem cells, healthy ke...
Read MoreNo Racial Differences Found in Access to Biologics: A Population-Based Study of Psoriasis Patients in the United States
August 2023 | Volume 22 | Issue 8 | Editorials | 835 | Copyright © August 2023
Background: Conflicting evidence exists regarding the role of race in access to biologics for patients with psoriasis. Objective: To compare biologic use among adult and pediatric Uni...
Read MoreDiagnosis and Management of Pediatric Psoriasis: An Overview for Pediatricians
August 2023 | Volume 22 | Issue 8 | Original Article | 742 | Copyright © August 2023
Pediatric psoriasis (PsO) and its associated comorbidities carry physical and psychosocial burdens in children and adolescents, which can negatively impact quality of life. However, features dist...
Read MorePsoriasis and Skin Barrier Dysfunction: The Role of Gentle Cleansers and Moisturizers in Treating Psoriasis
August 2023 | Volume 22 | Issue 8 | Original Article | 773 | Copyright © August 2023
Background: Psoriasis is a chronic immune-mediated dermatologic disorder with multisystemic comorbidities, which is effectively treated with a range of prescription therapies. St...
Read MoreTildrakizumab in Combination With Topical Halcinonide 0.1% Ointment for Treating Moderate to Severe Plaque Psoriasis
August 2023 | Volume 22 | Issue 8 | Original Article | 766 | Copyright © August 2023
Background: This prospective, open-label study evaluated the effectiveness and safety of tildrakizumab plus topical halcinonide ointment in psoriasis patients.Read More A Review of Tapinarof: Novel Topical Treatment for Plaque Psoriasis in Adults
August 2023 | Volume 22 | Issue 8 | Original Article | 761 | Copyright © August 2023
Psoriasis is a chronic, immune-mediated, multisystem, inflammatory dermatological condition that is persistent and relapsing. Topical treatments are first line agents for mild to moderate plaque ...
Read MoreReal-World Effectiveness and Safety of Tildrakizumab in Patients With Moderate-to-Severe Psoriasis: Week 28 Interim Analysis of a Phase 4 Study
August 2023 | Volume 22 | Issue 8 | Original Article | 754 | Copyright © August 2023
Background: Tildrakizumab is an anti–interleukin-23 p19 monoclonal antibody approved for the treatment of adults with moderate-to-severe plaque psoriasis. This analysis eva...
Read MoreTapinarof, a Novel, First-in-Class, Topical Therapeutic Aryl Hydrocarbon Receptor Agonist for the Management of Psoriasis
August 2023 | Volume 22 | Issue 8 | Original Article | 779 | Copyright © August 2023
Topical treatments remain the foundation of psoriasis management. Tapinarof (VTAMA®; Dermavant Sciences, Inc.) is a first-in-class, non-steroidal, topical, aryl hydrocarbon receptor (AhR) ago...
Read MoreTalquetamab-Induced Grover's Disease
August 2023 | Volume 22 | Issue 8 | Case Reports | 828 | Copyright © August 2023
Kresch M, Guénin S, Mubasher A, et al. Talquetamab-induced Grover’s disease. J Drugs Dermatol. 2023;22(8):828-829. doi:10.36849/JDD.7170...
Read MoreRacial Disparities in Primary Therapy for Newly Diagnosed Psoriasis Patients
July 2023 | Volume 22 | Issue 7 | Features | 715 | Copyright © July 2023
Women of Childbearing Age With Hidradenitis Suppurativa Frequently Prescribed Medications With Pregnancy Risk
July 2023 | Volume 22 | Issue 7 | Editorials | 706 | Copyright © July 2023
Copy: Hidradenitis suppurativa (HS) disproportionately affects women of childbearing age. As almost half of pregnancies in the United States are unplanned, dermatologists must gi...
Read MoreIntegrating Precision Medicine into Medical Dermatology Clinical Practice: An Expert Consensus Panel
June 2023 | Volume 22 | Issue 6 | Original Article | 588 | Copyright © June 2023
Background: Precision medicine utilizes an individual’s genomics to improve diagnosis, prognosis, and therapy. The joint American Academy of Dermatology and National Psoria...
Read MoreBiologic Vs Conventional Therapies: Comparing Risk of Psoriasis-Associated Comorbidities
June 2023 | Volume 22 | Issue 6 | Original Article | 621 | Copyright © June 2023
Psoriasis is associated with multiple comorbidities. In this retrospective cohort analysis, we compared the comorbidities in patients who received biologic treatments with those who received conventio...
Read MoreAnti-Tumor Necrosis Factor Alpha Therapeutic Drug Monitoring in Inflammatory Disease: A Systematic Review
May 2023 | Volume 22 | Issue 5 | Original Article | 445 | Copyright © May 2023
Background: Monoclonal antibodies encompass an increasingly important treatment for a variety of dermatologic conditions including hidradenitis suppurativa (HS). The high failure...
Read MoreThe Overview of the Immunobiology of Interleukin-23 Associated With Immune-Mediated Inflammatory Disorders: A Narrative Review
April 2023 | Volume 22 | Issue 4 | Original Article | 375 | Copyright © April 2023
Background: Interleukin (IL)-23, a member of the IL-12 family, has emerged as an important cytokine that bridges the innate and adaptive immune systems and plays a critical role ...
Read MorePatient Preferences in Topical Psoriasis Treatment
April 2023 | Volume 22 | Issue 4 | Original Article | 326 | Copyright © April 2023
Background: Psoriasis is a common inflammatory skin condition that varies in severity. Most patients have limited disease amenable to topical treatment; however, poor treatment a...
Read MoreEvaluating Sentiment, Engagement, and Perception of Biologics Among Patients with Psoriasis and Psoriatic Arthritis on Reddit
March 2023 | Volume 22 | Issue 3 | Features | 306 | Copyright © March 2023
Background: Limited analyses of social media content among psoriasis (PsO) and psoriatic arthritis (PsA) patients exist. These patients may turn to social media to gain insight i...
Read MoreBreaking the Frustrating Cycle of Topical Steroids in Psoriasis: A Review of a Novel Vehicle for Fixed-Dose Combination Halobetasol Propionate/Tazarotene
March 2023 | Volume 22 | Issue 3 | Original Article | 247 | Copyright © March 2023
Media and other results for: "biologics"